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Abstract
Background: Chronic fatigue syndrome (CFS) is defined by symptoms and disability, has no
confirmatory physical signs or characteristic laboratory abnormalities, and the etiology and
pathophysiology remain unknown. Difficulties with accurate case ascertainment contribute to this
ignorance.
Methods: Experienced investigators from around the world who are involved in CFS research met
for a series of three day workshops in 2000, 2001 and 2002 intended to identify the problems in
application of the current CFS case definition. The investigators were divided into focus groups and
each group was charged with a topic. The investigators in each focus group relied on their own
clinical and scientific knowledge, brainstorming within each group and with all investigators when
focus group summaries were presented. Relevant literature was selected and reviewed
independent of the workshops. The relevant literature was circulated via list-serves and resolved
as being relevant by group consensus. Focus group reports were analyzed and compiled into the
recommendations presented here.
Results: Ambiguities in the current CFS research definition that contribute to inconsistent case
identification were identified. Recommendations for use of the definition, standardization of
classification instruments and study design issues are presented that are intended to improve the
precision of case ascertainment. The International CFS Study Group also identified ambiguities
associated with exclusionary and comorbid conditions and reviewed the standardized,
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internationally applicable instruments used to measure symptoms, fatigue intensity and associated
disability.
Conclusion: This paper provides an approach to guide systematic, and hopefully reproducible,
application of the current case definition, so that case ascertainment would be more uniform across
sites. Ultimately, an operational CFS case definition will need to be based on empirical studies
designed to delineate the possibly distinct biological pathways that result in chronic fatigue.
Background
Chronic fatigue syndrome is a complex illness defined by
unexplained disabling fatigue and a combination of non-
specific accompanying symptoms. Similar disorders have
been described for at least two centuries and have been
variously named neurasthenia, myalgic encephalomyeli-
tis, Akureyri disease, post-viral fatigue, and chronic mono-
nucleosis [1]. The first formal case definition, published
in the United States in 1988 [2], suggested the name
"chronic fatigue syndrome" or CFS, which was retained in
subsequent Australian [3] and British [4] case definitions.
In 1994, an international collaborative group that
included authors of the previous case definitions pub-
lished the current CFS research case definition [5].
Although, the 1994 case definition comprises the current
international standard for classification of research sub-
jects as CFS, there are substantial differences between the
earlier definitions and it is important to understand this
when interpreting results of research studies. CFS is iden-
tified by symptoms and disability and by excluding ill-
nesses that could explain them. There are no confirmatory
physical signs or characteristic laboratory abnormalities.
The etiology and pathophysiology of the syndrome
remain unknown, and there is a lack of consensus in the
findings of many well-conducted studies both within and
between centers [6]. Difficulties with accurate case ascer-
tainment are a major contributor to this problem. Much
of the difficulty reflects conceptual and operational prob-
lems inherent in classifying an illness defined by symp-
toms and reported disability [7].
The objective of this article is to identify ambiguities in the
current CFS case definition that contribute to inconsistent
case identification and to recommend revisions for
improving the precision of case ascertainment for research
studies. This document is the product of three structured
meetings of international experts in CFS, representing epi-
demiology, infectious diseases, endocrinology, immunol-
ogy, neurology, psychology, psychiatry, biostatistics, and
patient advocacy. While recognizing the need for a more
consistently applied definition, the group resolved the
need for empirical studies designed to delineate the differ-
ent syndromes contained in unexplained fatigue. While
intended to apply primarily to the research setting, many
of our recommendations will be useful for health care
providers (and the patient community they serve) because
they suggest standardized instruments to record and to
measure the key symptom domains and the disability
associated with CFS.
Methods
From May of 2000 to May of 2002, the Centers for Disease
Control and Prevention (CDC) sponsored a series of
three-day workshops to discuss issues related to the cur-
rent CFS research definition. Each workshop was attended
by approximately 20 invited participants that represented
an international mix of scientists, clinicians and medical
researchers and approximately 10 CDC staff members.
During the first workshop, focus groups were formed to
address standardization and utilization of instruments
used to classify CFS. Each focus group then prepared a
summary report. The process that each focus group used
included reliance on clinical and scientific knowledge,
brainstorming, consensus building and literature reviews.
Each focus group report was presented to all workshop
participants for further discussion and was modified if
necessary. Interval periods between workshops were used
for independent review of relevant literature. The papers
were circulated via list-serves and resolved as relevant by
group consensus either on-line or during the subsequent
workshop. Workshop summaries and focus group reports
were analyzed and compiled into the recommendations
presented here. Where recommendations for specific eval-
uation instruments were made, wherever possible we
favored those that were freely available in the public
domain and validated across various language and cul-
tural groups.
Results
Exclusionary and Comorbid Conditions
The 1994 CFS case definition [5] recommends that
patients with severe chronic fatigue undergo a clinical
evaluation to identify underlying, contributing, and
comorbid conditions that require treatment. The lists of
exclusionary diagnoses used to screen subjects for enroll-
ment into CFS studies provided by the 1994 case defini-
tion were not exhaustive, but rather were examples to
guide investigators in their decisions. To increase the uni-
formity of decisions about exclusionary conditions, we
have further clarified exclusionary criteria and give more
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exhaustive recommendations of conditions that should
be excluded.
Examples of permanent medical exclusions include the
following: 1) organ failure (e.g., emphysema, cirrhosis,
cardiac failure, chronic renal failure); 2) chronic infec-
tions (e.g., AIDS, hepatitis B or C); 3) rheumatic and
chronic inflammatory diseases (e.g., systemic lupus ery-
thematosis, Sjogren's syndrome, rheumatoid arthritis,
inflammatory bowel disease, chronic pancreatitis); 4)
major neurologic diseases (e.g., multiple sclerosis, neu-
romuscular diseases, epilepsy or other diseases requiring
ongoing medication that could cause fatigue, stroke, head
injury with residual neurologic deficits); 5) diseases
requiring systemic treatment (e.g., organ or bone marrow
transplantation, systemic chemotherapy, radiation of
brain, thorax, abdomen, or pelvis); 6) major endocrine
diseases (e.g., hypopituitarism, adrenal insufficiency); 7)
primary sleep disorders (e.g., sleep apnea, narcolepsy).
Temporary medical exclusions include treatable condi-
tions that require evaluation over time to determine the
extent to which they contribute to the fatiguing illness.
These encompass four general categories: 1) conditions
discovered at onset or initial evaluation (e.g., effects of
medications, sleep deprivation, untreated hypothy-
roidism, untreated or unstable diabetes mellitus, active
infection); 2) conditions that resolve (e.g., pregnancy
until 3 months post-partum, breast feeding, major surger-
ies until 6 months post-operation, minor surgery until 3
months post-operation, and major infections such as sep-
sis or pneumonia until 3 months post-resolution; sleep
disorders such as restless leg syndrome and periodic limb
movement should be considered temporary exclusions
for research criteria, if they are severe, but not if the degree
of the sleep problem is insufficient to explain the severity
of the fatigue); 3) major conditions whose resolution may
be unclear for at least 5 years (e.g., myocardial infarction,
heart failure); and 4) morbid obesity (body mass index
[BMI] > 40). The 1994 CFS case definition specified a BMI
> 45. While both cut-off values are arbitrary, a BMI > 40
defines morbid obesity and is a more inclusive contribut-
ing factor to explain chronic fatigue.
Permanent psychiatric exclusions include lifetime diag-
noses of bipolar affective disorders, schizophrenia of any
subtype, delusional disorders of any subtype, dementias
of any subtype, organic brain disorders, and alcohol or
substance abuse within 2 years before onset of the fatigu-
ing illness. The 1994 case definition stated that any past or
current diagnosis of major depressive disorder with psy-
chotic or melancholic features, anorexia nervosa, or
bulimia permanently excluded a subject from the classifi-
cation of CFS. Because these illnesses may resolve with lit-
tle or no likelihood of recurrence and only active disease
or disease requiring prophylactic medication would con-
tribute to confusion with evaluation of CFS symptoms, we
now recommend that if these conditions have been
resolved for more than 5 years before the onset of the cur-
rent chronically fatiguing illness, they should not be con-
sidered exclusionary.
Reliable detection of psychiatric illness requires a struc-
tured interview conducted during clinical evaluation of
persons suspected to have CFS. We recommend the Com-
posite International Diagnostic Instrument (CIDI) [8].
The CIDI is a computerized structured psychiatric inter-
view that can be administered by general medical person-
nel and is supported by the World Health Organization
(WHO) (for further information see http://www.who.int/
msa/cidi/ or http://www.who.int/msa/cidi/listofcon
tacts.htm). The CIDI has been widely used in large epide-
miologic studies and therefore allows for national com-
parisons of psychiatric prevalence rate. Alternatively, the
Structured Clinical Interview for DSM-IV Axis 1 (SCID)
[9] may be utilized. However, trained interviewers (i.e.,
psychiatrists, clinical psychologists, psychiatric social
workers, psychiatric nurse practitioners or research nurses
with experience in psychiatric assessments) must admin-
ister the SCID. Both paper and pencil and computer
assisted versions of the SCID are available (for further
information see http://cpmcnet.columbia.edu/dept/scid/
). The SCID is better suited for clinical studies. However,
because of the difference in how they are administered,
the SCID and CIDI often do not produce comparable
results. These differences must be considered in evaluating
study results and comparing studies. Any study must spec-
ify which psychiatric instrument was used and discuss its
strengths and weaknesses when interpreting results.
Definition and Evaluation of Fatigue
Several instruments that measure fatigue have been used
in studies of CFS. The instruments have considerable over-
lap and each has advantages and disadvantages. We rec-
ommend that research studies of CFS consider using the
more extensive Checklist Individual Strength, but shorter
instruments such as the Chalder and Krupp scales are also
appropriate. The Checklist Individual Strength (CIS) [10]
is a 20-item inventory with 4 subscales: fatigue severity,
concentration, reduced motivation and, physical activity.
The fatigue severity subscale measures both general and
physical fatigue and a score above 36 represents severe
fatigue. The CIS focuses on fatigue over the preceding two
weeks. Considerable normative data have been collected
with reference to both CFS and post cancer patients and it
has been used in epidemiological studies [11-13].
The Chalder Fatigue Scale [14] is a 14-item instrument
with a 4-choice format that measures fatigue intensity and
separates mental and physical fatigue. The Chalder scale
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has been used in large community samples and has pub-
lished receiver-operating characteristics [15].
The Krupp Fatigue Severity Scale [16] includes 9 items
rated on 7-point scales and is sensitive to different aspects
and gradations of fatigue severity. Most items in the Krupp
scale are related to behavioral consequences of fatigue.
Patients with similar fatigue intensity may have widely
divergent levels of disability. Assessment of CFS patients
must also evaluate functional disability associated with
the overall illness. Research studies should stratify CFS
subjects according to the level of disability, but consensus
as to which scales are most relevant has not been
achieved. Four scales should be considered in this context;
two are questionnaires of functional disability and two
measure daily activity. We recommend that research stud-
ies use either the Medical Outcomes Survey Short Form-
36, or if disability is a major focus of the study (e.g., treat-
ment trials), then we recommend the more detailed Sick-
ness Impact Profile.
The Medical Outcomes Survey Short Form-36 (MOS SF-
36) is a well-validated instrument that measures the
effects of the entire illness (i.e., fatigue and accompanying
symptoms) on physical activity, social activity, usual role
activities, bodily pain, general mental health, vitality, and
general health perceptions [17]. Considerable normative
data are available for many illnesses including CFS
[18,19].
The Sickness Impact Profile (SIP) [20] measures func-
tional disability in different areas of daily functioning.
Eight subscales of the 12 available are generally used in
CFS: alertness behavior, sleep, homemaking, leisure activ-
ities, work, mobility, social interactions, and ambulation.
Like the MOS SF-36, the SIP measures the consequences
of the entire illness. However, the SIP records disability in
concrete activities, which makes it less dependent on sub-
jective impression.
The Activity record (ACTRE) is a self-administered 2-day
diary of physical activity that has been used to obtain a
profile of functioning and dysfunction [21]. To objec-
tively record physical activity, study subjects can be mon-
itored by actigraphy. Actigraphy data can be collected over
days or weeks, and the intensity of activity patterns can be
analyzed [22-25]. Comparisons of physical activity meas-
ured by actigraphy and by self-report show only a weak
correlation [23].
Definition and Evaluation of Accompanying Symptoms
The 1994 case definition defines CFS by the presence of
debilitating fatigue accompanied by at least 4 of 8 desig-
nated symptoms. Accompanying symptoms must have
persisted or recurred during 6 or more consecutive
months of illness and cannot have predated the fatigue.
Designated accompanying symptoms include the follow-
ing: post-exertional malaise lasting more than 24 hours;
unrefreshing sleep; impaired short-term memory or con-
centration severe enough to cause substantial reduction in
previous levels of occupational, educational, social, or
personal activities; headaches of a new type, pattern, or
severity; muscle pain; multi-joint pain without swelling or
redness; sore throat; and tender cervical/axillary lymph
nodes. It is important to stress that these are symptoms
not signs. Signs such as inflamed tonsils or swollen lymph
nodes should prompt the search for alternative diagnoses.
These symptoms are non-specific and variable in both
nature and severity over time. They were selected on the
basis of consensus clinical opinion and were not identi-
fied empirically. We recommend that research studies use
the SPHERE (discussed below) to query subjects (cases
and controls) about the occurrence, duration, and severity
of the 8 case defining symptoms and other potentially
accompanying symptoms.
Impact of the cumulative symptom complex should be
the primary determinant in the classification of CFS. The
MOS SF-36 and SIP (discussed above) measure overall
disability. The remainder of this section discusses recom-
mended standardized instruments to measure sleep, cog-
nition, and pain. The information derived from these
instruments will allow the identification of subgroups of
subjects classified as CFS according to their clinical char-
acteristics and disability [6].
The Group was not aware of an internationally standard-
ized and validated instrument that measures the cumu-
lated symptom complex of CFS. We recommend that
investigators use the Somatic and Psychological Health
Report (SPHERE) as a screening instrument for potential
participants in research studies of CFS. The SPHERE is a
36-item instrument that identifies severe and disabling
fatigue and measures accompanying symptoms and
somatic distress by combining questions from the General
Health Questionnaire (GHQ-30) and the CIDI. The
SPHERE allows for concurrent measurement of depres-
sion, anxiety, somatization disorder and fatigue as inde-
pendent constructs, hence its utility as a screening
instrument in studies of CFS [26]. It has been used exten-
sively in studies of primary care patients [27], and patients
with post-infective and post-cancer fatigue [28]. However,
it does not address fatigue in the same detail as other
scales nor is it an acceptable substitute for standardized
psychiatric screening instruments.
However, the SPHERE does not assess the entire symptom
complex in detail and screens only for depression and
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anxiety and not for exclusionary psychiatric conditions.
Therefore investigators should consider using the publicly
available Centers for Disease Control and Prevention
Symptom Checklist http://www.cdc.gov/ncidod/diseases/
cfs/index.htm. This checklist has not been formally vali-
dated but it has been used in several population-based
studies so that comparative data is available. The use of a
common instrument to assess the accumulated symptom
complex of CFS would lead to standardization and valida-
tion.
To measure sleep, cognition, and pain we recommend the
following standardized instruments.
Sleep disturbance
Systematic evaluation with objective sleep studies is not
practical (or necessary) in most CFS studies, and we rec-
ommend two instruments for use in CFS research studies.
The Pittsburgh Sleep Questionnaire was developed to
measures sleep quality in psychiatric research [29]. The
Sleep Assessment Questionnaire (SAQ), a 17-item instru-
ment developed by Moldofsky and collaborators, meas-
ures seven factors: insomnia/hypersomnia, restlessness,
sleep schedules, excessive daytime sleeping, sleep apnea,
restless leg/motility, and non-restorative sleep [30-32].
The SAQ has been validated against data obtained from
polysomnography. The instrument and substantial sup-
port, including scoring and data maintenance, are availa-
ble via the internet http://sleepmed.to. However, the
instrument is proprietary and a fee is charged for its use.
Of note, sleep scales that measure somnolence rather than
unrefreshing sleep are not adequate for studies of CFS.
These include visual analogue scales such as the Epworth
and Stanford Sleepiness Scales [33,34].
Neurocognitive functioning
Impaired short-term memory or concentration severe
enough to cause substantial reduction in previous levels
of occupational, educational, social, or personal activities
is a case defining symptom and is reported by most per-
sons with CFS. The deficit appears to be global but non-
specific deficit most notably in the areas of attention and
information processing. Newly emerging technology (e.g.,
functional neuroimaging) may complement and eventu-
ally replace traditional neurocognitive function tests.
However, the Group did not recommend specific imaging
measurements at this time.
Three alternatives to traditional neuropsychological test-
ing should be considered in the CFS research setting. The
Cambridge Neuropsychological Test Automated Battery
(CANTAB) is currently the most practical single tool to
assess cognition in CFS research studies [35,36]. The CAN-
TAB includes tests of memory, attention, and executive
function and is administered via a touch-sensitive compu-
ter screen. The CANTAB allows a decomposition of com-
plex tasks commonly used in clinical assessment into their
cognitive components. Tests include versions of the Wis-
consin Card-Sorting Test, the Tower of London, and the
Delayed Matching-to-Sample Test. The CANTAB is non-
verbal and largely language and culture independent. It
has been standardized and validated in the elderly
[37,38], and in patients with depression [39], other mood
disorders [40], schizophrenia [41], Alzheimer's disease
[42], and CFS [43]. Unfortunately, the CANTAB is propri-
etary and relatively expensive.
The Australian Group (Ute Vollmer-Conna and Jim
Lemon, personal communication) has developed the
Rozelle Test Battery (RTB), that, similar to the CANTAB, is
administered on laptop computers. Like the CANTAB, the
RTB consists of mostly non-verbal tests, thus minimizing
language and culture biases. Six tests from the RTB com-
prise the RTB-Fatigue battery and were selected to detect
subtle cognitive impairment in the domains likely to be
affected in CFS (attention, working memory, information
processing, and mental flexibility) and were selected to
allow repeated trials. Tests included in the RTB-Fatigue
were derived from public domain standardized neurocog-
nitive instruments and include versions of the Symbol
Digit test, the Stroop Color-Word test, the Tower of Lon-
don, a Spatial Memory Search test, a Concurrent Attention
task, and a Task Shifting test. The RTB-Fatigue has been
used in studies of CFS [44]. Finally, the hardware, operat-
ing system, and programming environment were selected
to provide an inexpensive, flexible testing system that
does not rely upon specialized or proprietary technology.
Recently, a Cognitive Function Index (CFI) for CFS has
been developed on a sample of 189 CFS subjects and 61
demographically matched controls by investigators at the
New Jersey Medical School (Gudrun Lange and Benjamin
Natelson personal communication). The CFI score is
comprised of two demographic factors (age and educa-
tion) and seven cognitive factors derived from a restricted
set of scores on standard neuropsychological assessment
instruments. Items are either non-verbal or available in
English, Spanish, and German. The CFI score represents a
weighted average of the nine factors and appears to dis-
criminate between CFS patients and controls (Benjamin
Natelson personal communication). Items include the
California Verbal Leaning Test, the Rey-Osterrieth Com-
plex Figure Test, the computerized NES continuous per-
formance test, the Trail Making Test A and B, the grooved
pegboard test, and the WAIS-III Vocabulary and Digit
Span subtests. For more information concerning the CFI
contact the investigators http://www.umdnj.edu/cfsweb/
CFS/cfshome.html.
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Pain
If characterization of pain is necessary, we recommend
using the McGill Pain Questionnaire. The McGill Pain
Questionnaire (MPQ) is well validated, relatively inex-
pensive, available in several languages, and in a short
form [45]. The 4 components of the MPQ include 1) a
human figure drawing on which patients are asked to
mark the location of their pain; 2) a series of 78 adjectives
divided into 20 groups from which patients identify their
experience by circling word descriptors; 3) questions
about prior pain experience, pain location, and informa-
tion on the use of pain medication; and 4) a present pain
intensity index. The short form (MPQ-SF) does not assess
areas of bodily involvement and, if used in CFS research
studies, should be supplemented by pain diagrams.
Discussion
Clinical evaluation of persons with a fatiguing illness
requires a thorough history that assesses physical and psy-
chological symptoms, social factors, and medications and
supplements that could contribute to fatigue; a thorough
physical examination, a mental status examination; and,
a minimum battery of laboratory tests. The presence of a
medical or psychiatric condition that may explain the
chronic fatigue state excludes the classification as CFS in
research studies because overlapping pathophysiology
may confound findings specific to CFS. The concept of
"exclusionary conditions" makes sense only in research
settings in which such distinction is required for clarity. In
clinical settings, exclusionary conditions provide a list of
differential or comorbid diagnoses that should be consid-
ered in patients with debilitating fatigue. This is important
because appropriate intervention for these disorders
could improve quality of life. In the clinical setting,
patients with exclusionary conditions may be diagnosed
and managed as having CFS on the basis of the physician's
medical opinion as to whether the exclusionary condition
is likely to be a major contributor to the patient's fatigue.
For the research definition of CFS, some exclusionary
medical diagnoses may be considered permanent if no
intervention will adequately resolve the condition. By
contrast, some medical conditions will resolve or are ade-
quately managed with treatment and should therefore be
considered temporary exclusions. Research studies should
stratify those individuals with apparently resolved medi-
cal conditions that otherwise meet the CFS case defini-
tion.
The 1994 case definition excluded psychiatric conditions
that prevent a subject from accurately reporting symptoms
and those with fatigue as a reasonably anticipated symp-
tom. Consistent application of these exclusionary criteria
has proven difficult because there was no recommenda-
tion as to how these conditions should be accurately and
rapidly detected. In addition, opinions have evolved as to
the best way to approach psychiatric diagnoses that may
arise as result of, or co-morbid with, CFS. The following
guidelines include recommendations for exclusionary
psychiatric conditions and for stratification of study sub-
jects.
The 1994 CFS case definition stipulates that patients have
the following: 1) clinically evaluated, unexplained, per-
sistent or relapsing chronic fatigue (of least 6 months
duration) that is of new or definite onset (i.e., has not
been lifelong), 2) is not the result of ongoing exertion; 3)
is not substantially alleviated by rest; and 4) results in sub-
stantial reduction in previous levels of occupational, edu-
cational, social, or personal activities [5]. These
descriptors of fatigue are difficult to apply in practice [46].
The stipulation that the fatigue is "of new or definite
onset" (i.e., has not been life long) was intended to
exclude subjects with personality or somatization disor-
ders that are characterized by a "lifelong pattern of presen-
tations to medical attention with unexplained symptoms"
[47]. We recommend that somatization disorder be iden-
tified and serve as a stratification diagnosis. Only subjects
who recount having always felt fatigued should be
excluded as having "lifelong" fatigue.
The stipulation that the fatigue be unrelated to ongoing
exertion was intended to distinguish the unexplained
fatigue in persons with CFS from that due to ongoing
physical demands. However, CFS patients have an exag-
gerated fatigue response to previously well-tolerated activ-
ities and many report their fatigue is unusually sensitive to
physical or mental exertion. Indeed, post-exertional
malaise lasting more than 24 hours is one of the accom-
panying symptoms that define CFS. Therefore, this
requirement should be interpreted as referring to exhaus-
tion unrelated to an excessively demanding schedule that
would induce fatigue in an otherwise healthy adult.
The requirement that rest should not substantially allevi-
ate the fatigue is also unclear. It was intended to exclude
the type of fatigue associated with overwork that resolves
when the excessive demands end. Most persons with CFS
experience some alleviation of fatigue and accompanying
symptoms if they rest, but this relief does not allow for
recovery of pre-illness physical and mental stamina. Some
CFS patients use resting as a strategy to avoid over-exer-
tion and the attendant exacerbation of symptoms. Thera-
peutic use of rest or a partial response to rest should not
exclude a subject's illness from classification as CFS.
Finally, reliance on an affirmation that the fatigue sub-
stantially limits performance of daily activities is insuffi-
cient because "substantial" limitation is undefined, and
independent confirmation of the reported level of disabil-
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ity is rarely sought. Fatigue is highly subjective, multidi-
mensional, and variable during the course of disease.
Ambiguities in the nature and severity of fatigue could be
reduced by assessing fatigue and associated symptoms in
a standardized manner. Measures of fatigue should
encompass both its intensity and associated disability
[48].
The 1994 case definition defines CFS by the presence of
debilitating fatigue accompanied by at least four of eight
designated symptoms. These symptoms are non-specific
and variable in both nature and severity over time. They
were selected on the basis of consensus clinical opinion
and were not identified empirically. Accompanying symp-
toms must have persisted or recurred during six or more
consecutive months of illness and cannot have predated
the fatigue. Designated accompanying symptoms include
the following: post-exertional malaise lasting more than
24 hours; unrefreshing sleep; impaired short-term mem-
ory or concentration severe enough to cause substantial
reduction in previous levels of occupational, educational,
social, or personal activities; headaches of a new type, pat-
tern, or severity; muscle pain; multi-joint pain without
swelling or redness; sore throat; and tender cervical/axil-
lary lymph nodes. It is important to stress that these are
symptoms not signs. Signs such as inflamed tonsils or
swollen lymph nodes should prompt the search for alter-
native diagnoses.
Most CFS patients report unrefreshing sleep. However,
narcolepsy and clinically significant obstructive sleep
apnea are considered exclusionary diagnoses. It is unclear
whether as yet-undefined sleep pathologies should be
considered as co-morbid features of CFS or as common
pathogenic pathways. Unrefreshing sleep accompanies a
variety of sleep disorders and may explain some fatiguing
illnesses [29]. Thus, assessment of sleep must detect treat-
able primary sleep disorders and evaluate sleep-related
symptoms that may be part of CFS.
CFS patients typically complain of difficulties with con-
centration, memory, and thinking, yet neuropsychologi-
cal testing does not generally confirm the reported
cognitive dysfunction [49,50]. The available data point to
a more global, but non-specific performance deficit possi-
bly related to impaired attention and slowed processing
speed [51]. Investigators should use the report of cogni-
tive impairment by the individual or a reliable informant
as an initial screening tool. Measurement of cognitive
function is complex, time consuming, and cannot be cur-
rently recommended for use in classifying CFS in research
studies. However, studies exploring the cognitive dimen-
sion of CFS should be high priority.
Five of the eight CFS-defining symptoms reflect pain
(headaches of a new type, pattern, or severity, muscle
pain, and multi-joint pain without swelling or redness,
sore throat, tender cervical/axillary lymph nodes). Pain
may be a result of, responsible for, or associated with,
both fatigue and sleep disturbances. Assessment of
chronic pain (such as that reported by patients with CFS)
includes a clinical history, physical examination, and psy-
chiatric screening, all of which are discussed above. The
SPHERE records sufficient information on the frequency
and extent of chronic pain for most CFS research studies.
However, pain may be the primary determinant of disa-
bility for some CFS patients. Chronic widespread pain
may be a stratifying factor in the analyses.
Conclusion
The intent of this article was to guide systematic and
reproducible application of the current case definition so
that case ascertainment will be more uniform across
research study sites. As part of this guide, we have recom-
mended several standardized and validated instruments
be used in assessments of fatigue, disability, and symp-
toms. If done, research studies on patients with CFS are
more likely to be comparable. We have offered sugges-
tions and examples to further clarify permanent medical
and temporary exclusions including the best way to
approach psychiatric diagnoses that may arise as result of,
or are co-morbid with, CFS. Since fatigue is highly subjec-
tive, multidimensional, and variable during the course of
disease, we have recommended approaches for standard-
ized assessment of the nature and severity of fatigue.
Finally, given that both the 1994 case definition and these
recommendations for the better application of that defini-
tion were derived by expert consensus, the International
CFS Study Group recommended a study of patients with
chronic unexplained fatigue from which a definition of
CFS can be empirically derived. The study should encom-
pass different regions and cultures and utilize the instru-
ments discussed here. To test the validity and reliability of
the CFS case definition as revised, prospective studies of
subjects at high risk for CFS should be undertaken.
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